JPWO2015037655A1 - Agents for reducing protein catabolism or promoting anabolism - Google Patents

Abstract

Provided is an agent capable of suppressing or preventing muscle loss in a nutritional disorder such as a dialysis patient or a person with such possibility by reducing protein catabolism or promoting assimilation in a human body. The amount of protein is 0.5 to 5 g per 100 kcal of energy, the amount of phosphorus is 10 to 50 mg, the amount of sodium is 10 to 100 mg, and the amount of potassium is 5 to 50 mg for reducing catabolism or promoting anabolism Agent. The agent can further contain lipids, sugars, minerals and water, and can be taken as a liquid food. In this case, per 100 kcal of energy, the amount of lipid is 1 to 5 g, the amount of carbohydrate is 10 to 20 g, and the energy per milliliter is 1 to 2 kcal.

Description

  The present invention relates to an agent for reducing protein catabolism or promoting anabolism.

It is an important issue for patients undergoing artificial dialysis for the treatment of kidney disease (hereinafter referred to as dialysis patients) whether or not protein-energy nutrition disorder (PEW) has occurred. is there.
Here, protein / energy malnutrition (PEW) refers to a state where protein and energy are deficient. Protein and energy malnutrition (PEW) is accompanied by a decrease in protein in skeletal muscle, serum, and the like, and is an important factor for grasping a patient's condition after surgery or after onset of illness.
Causes of protein and energy malnutrition (PEW) in dialysis patients include insufficiency of protein intake and energy due to decreased appetite, loss of amino acids and proteins in artificial dialysis therapy (excretion into dialysate), Examples include increased catabolism (degradation) of muscle proteins and inflammation of skeletal muscles.

Reduction of muscle protein catabolism (degradation) or promotion of assimilation (generation) reduces the exhaustion of physical strength due to muscle loss, for dialysis patients such as dialysis patients who have limited intake of protein and water, It is beneficial.
Conventionally, various methods for reducing protein catabolism are known.
For example, Patent Document 1 discloses a method of using a composition containing a proteinaceous substance in the manufacture of a medicament for treating a subject suffering from insulin resistance, wherein the proteinaceous substance has an energy value of the composition. The above method is described which provides at least 24.0% and at least 12% by weight of leucine based on proteinaceous material.

Patent Document 2 discloses a method for treating muscle loss in an individual, wherein the branched chain amino acid (BCAA), BCAA precursor, BCAA metabolite, BCAA-rich protein, or protein manipulated to increase BCAA content. At least one of the following: administering to the individual at least one effective amount of: BCAA, BCAA precursor, BCAA metabolite, BCAA-rich protein, and protein engineered to increase BCAA content A method for antagonizing catabolism is described.
In addition, US Pat. No. 6,057,049 is a composition suitable for affecting recovery from intense physical activity in animals, comprising about 4% to 6% easily absorbable carbohydrates, about 10% to 30%. A composition comprising maltodextrin and about 20% to 50% starch, a total of about 40% to 80% carbohydrate, and about 20% to about 40% protein is described.

Special table 2009-511576 gazette Special table 2009-517473 Special table 2011-511070 gazette

None of the techniques described in Patent Documents 1 to 3 described above have proved their effects by tests on the human body.
An object of the present invention is to provide an agent capable of suppressing or preventing muscle loss in a person having or possibly having a nutritional disorder such as a dialysis patient by reducing protein catabolism or promoting anabolism in the human body. To do.

  As a result of intensive studies to solve the above problems, the present inventors have found that the amount of protein is 0.5 to 5 g, the amount of phosphorus is 10 to 50 mg, the amount of sodium is 10 to 100 mg, and the amount of potassium per 100 kcal of energy. The present invention has been found that an agent of 5 to 50 mg can reduce protein catabolism or promote anabolism in the human body, and can suppress or prevent exhaustion of physical strength due to muscle loss. .

The present invention provides the following [1] to [12].
[1] Protein catabolism characterized in that the amount of protein is 0.5 to 5 g, the amount of phosphorus is 10 to 50 mg, the amount of sodium is 10 to 100 mg, and the amount of potassium is 5 to 50 mg per 100 kcal of energy. Agents for reducing or promoting anabolism.
[2] An agent for reducing catabolism or promoting anabolism of protein that can be ingested as a liquid food, including protein, lipid, sugar, mineral and water, and the amount of protein is 0.5 to 5 g per 100 kcal of energy. The amount of lipid is 1 to 5 g, the amount of carbohydrate is 10 to 20 g, the amount of phosphorus is 10 to 50 mg, the amount of sodium is 10 to 100 mg, the amount of potassium is 5 to 50 mg, and the energy per milliliter is An agent for reducing catabolism or promoting anabolism of a protein, characterized by being 1 to 2 kcal.
[3] Contains vitamins, and per 100 kcal of energy, the amount of calcium is 10 to 50 mg, the amount of magnesium is 5 to 30 mg, the amount of iron is 0.2 to 2 mg, the amount of zinc is 0.2 to 2 mg, vitamins The agent for reducing catabolism or promoting anabolism according to the above [1] or [2], wherein the amount of A is 10 to 100 μg RE and the amount of vitamin D is 0.1 to 0.5 μg.
[4] The agent for reducing catabolism or promoting anabolism according to any one of [1] to [3] above, wherein the volume of one dose is 100 to 300 ml.
[5] The agent for reducing catabolism or promoting anabolism of the protein according to any one of [1] to [4] for use in a dialysis patient.

[6] The agent for reducing protein catabolism or promoting anabolism is obtained by subtracting the value of amino acid concentration in arterial blood in a non-ingested state from the value of amino acid concentration in arterial blood 3 hours after the intake of the agent. The agent for reducing catabolism or promoting anabolism according to any one of the above [1] to [5], wherein the obtained value is for oral administration to those who become 0 or more.
[7] Reduction of protein catabolism of an agent having an amount of protein of 0.5 to 5 g, an amount of phosphorus of 10 to 50 mg, an amount of sodium of 10 to 100 mg, and an amount of potassium of 5 to 50 mg per 100 kcal of energy Use to promote assimilation.
[8] An agent that can be ingested as a liquid food containing protein, lipid, carbohydrate, mineral and water, and the amount of protein is 0.5 to 5 g, the amount of lipid is 1 to 5 g, and sugar per 100 kcal of energy. The amount of protein is 10 to 20 g, the amount of phosphorus is 10 to 50 mg, the amount of sodium is 10 to 100 mg, the amount of potassium is 5 to 50 mg and the energy per milliliter is 1 to 2 kcal. Use to reduce catabolism or promote anabolism.
[9] Contains vitamins, and per 100 kcal of energy, the amount of calcium is 10 to 50 mg, the amount of magnesium is 5 to 30 mg, the amount of iron is 0.2 to 2 mg, the amount of zinc is 0.2 to 2 mg, vitamins Use of the agent according to the above [7] or [8], wherein the amount of A is 10 to 100 μg RE and the amount of vitamin D is 0.1 to 0.5 μg for reducing catabolism or promoting anabolism.
[10] Use of the agent according to any one of [7] to [9] above, wherein the volume of one dose is 100 to 300 ml.
[11] Use of the agent according to any one of [7] to [10] above for dialysis patients.
[12] The use of the above agent is such that the value obtained by subtracting the value of the amino acid concentration in arterial blood in a non-ingested state from the value of the amino acid concentration in arterial blood 3 hours after the intake of the agent is 0 or more. Use of the agent according to any one of [7] to [11] above, wherein the agent is used for oral administration to an adult.

  According to the agent for reducing catabolism or promoting anabolism of the present invention (hereinafter also referred to as the agent of the present invention), by reducing protein catabolism or promoting anabolism in the human body, Muscle loss can be suppressed or prevented in potential individuals.

The agent for reducing catabolism or promoting anabolism of the protein of the present invention has a protein amount of 0.5 to 5 g, a phosphorus amount of 10 to 50 mg, a sodium amount of 10 to 40 mg, and a potassium amount of 100 kcal of energy. 5 to 50 mg.
The amount of these proteins will be described in detail below.
The amount of protein is 0.5 to 5 g, preferably 1 to 5 g, more preferably 2 to 4.5 g, and particularly preferably 3 to 4 g per 100 kcal of energy of the agent of the present invention. If the amount is less than 0.5 g, it is difficult to give a sufficient amount of protein to the intaker. When the amount exceeds 5 g, when the intake person is a person who is restricted in the intake of protein such as a dialysis patient, the amount of protein becomes excessive, and the degree of improvement of the intake person's kidney function and the like is increased. May be lower.

The amount of phosphorus (P) is 10 to 50 mg, preferably 20 to 50 mg, more preferably 25 to 45 mg, particularly preferably 30 to 40 mg per 100 kcal of energy of the agent of the present invention. If the amount is less than 10 mg, it is difficult to give a sufficient amount of phosphorus to the intaker. When the amount exceeds 50 mg, when the intake person is a person whose intake of phosphorus is restricted, such as a dialysis patient, the amount of phosphorus becomes excessive, and the degree of improvement in the kidney function and the like of the intake person is increased. May be lower.
The amount of sodium (Na) is 10 to 100 mg, preferably 20 to 90 mg, more preferably 30 to 80 mg, particularly preferably 40 to 80 mg per 100 kcal of energy of the agent of the present invention. If the amount is less than 10 mg, it is difficult to give a sufficient amount of sodium to the intaker. When the amount exceeds 100 mg, when the intake person is a person whose intake of sodium is restricted, such as a dialysis patient, the amount of sodium becomes excessive, and the degree of improvement in the kidney function and the like of the intake person is reduced. May be lower.

The amount of potassium (K) is 5 to 50 mg, preferably 10 to 45 mg, more preferably 15 to 40 mg, and particularly preferably 20 to 40 mg per 100 kcal of energy of the agent of the present invention. If the amount is less than 5 mg, it is difficult to give a sufficient amount of potassium to the intaker. When the amount exceeds 100 mg, when the intake person is a person whose intake of potassium is restricted, such as a dialysis patient, the amount of potassium becomes excessive, and the degree of improvement in the kidney function and the like of the intake person is reduced. May be lower.
In the present invention, when the amounts of protein, phosphorus, sodium and potassium per 100 kcal of energy are within the above-mentioned ranges, the effect of reducing catabolism or promoting anabolism can be obtained.

The agent of the present invention can contain lipids, carbohydrates, other minerals (other than phosphorus, sodium and potassium), vitamins and water in addition to proteins, phosphorus, sodium and potassium. In this case, since the agent of the present invention contains water, it can be taken orally as a liquid food.
Preferable examples of lipids include medium chain fatty acid triglycerides.
The amount of lipid is preferably 1 to 5 g, more preferably 1.5 to 4.5 g, and particularly preferably 2 to 4 g per 100 kcal of energy of the agent of the present invention. If the amount is less than 1 g, it is difficult to give a sufficient amount of lipid to the intaker. When the amount exceeds 5 g, the amount of lipid becomes excessive, and the nutritional balance necessary for the intake person may be deteriorated.
Preferable examples of the saccharide include soluble polysaccharides (eg, dextrin, oligosaccharide, etc.).
The amount of the saccharide is preferably 10 to 20 g, more preferably 12 to 18 g, and particularly preferably 14 to 17 g per 100 kcal of energy of the agent of the present invention. If the amount is less than 10 g, it is difficult to give a sufficient amount of carbohydrates to the intake person. If the amount exceeds 20 g, the amount of carbohydrates may become excessive, and the nutritional balance necessary for the intake person may be deteriorated.

Examples of other minerals (other than phosphorus, sodium, and potassium) include calcium, magnesium, iron, and zinc.
The amount of calcium (Ca) is preferably 10 to 50 mg, more preferably 15 to 45 mg, and particularly preferably 20 to 40 mg per 100 kcal of energy of the agent of the present invention. If the amount is less than 10 mg, it is difficult to give a sufficient amount of calcium to the intaker. When the amount exceeds 50 mg, the amount of calcium becomes excessive, and the nutritional balance necessary for the intake person may be deteriorated.
The amount of magnesium (Mg) is preferably 5 to 30 mg, more preferably 5 to 25 mg, and particularly preferably 10 to 20 mg per 100 kcal of energy of the agent of the present invention. If the amount is less than 5 mg, it is difficult to give a sufficient amount of magnesium to the intaker. If the amount exceeds 30 mg, the amount of magnesium becomes excessive, and the nutritional balance necessary for the intakeer may be deteriorated. The degree of improvement may be low.

The amount of iron (Fe) is preferably 0.2 to 2 mg, more preferably 0.4 to 1.5 mg, and particularly preferably 0.6 to 1.2 mg per 100 kcal of energy of the agent of the present invention. If the amount is less than 0.2 mg, it is difficult to give a sufficient amount of iron to the intaker. If the amount exceeds 2 mg, the amount of iron may be excessive, and the nutritional balance necessary for the intake person may be deteriorated.
The amount of zinc is preferably 0.2 to 2 mg, more preferably 0.3 to 1.5 mg, particularly preferably 0.5 to 1.2 mg per 100 kcal of energy of the agent of the present invention. When the amount is less than 0.2 mg, it is difficult to give a sufficient amount of zinc to the intaker. When the amount exceeds 2 mg, the amount of zinc becomes excessive, and the nutritional balance necessary for the intake person may be deteriorated.

Examples of vitamins include vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, and vitamin C.
The amount of vitamin A is preferably 10 to 100 μg RE (retinol equivalent), more preferably 20 to 80 μg RE, particularly preferably 40 to 80 μg RE per 100 kcal of energy of the agent of the present invention. If the amount is less than 10 μg RE, it is difficult to give a sufficient amount of vitamin A to the intaker. When the amount exceeds 100 μg RE, there is a possibility that the degree of improvement in kidney function or the like may be reduced for patients with renal insufficiency and the like in which vitamin A intake is limited.
The amount of vitamin D is preferably 0.05 to 0.5 μg, more preferably 0.05 to 0.3 μg, and particularly preferably 0.1 to 0.2 μg per 100 kcal of energy of the agent of the present invention. When the amount is less than 0.05 μg, it is difficult to give a sufficient amount of vitamin D to the intaker. When the amount exceeds 0.5 μg, there is a possibility that the degree of improvement in kidney function and the like is low for renal failure patients and the like whose vitamin D intake is limited.

Vitamin E, vitamin B1, vitamin B2, vitamin C and the like may be appropriately blended with reference to normal amounts necessary for the human body.
The amount of vitamin E is usually 0.5 to 2 mg per 100 kcal of energy of the agent of the present invention.
The amount of vitamin B1 is usually 0.05 to 0.2 mg per 100 kcal of energy of the agent of the present invention.
The amount of vitamin B2 is usually 0.05 to 0.2 mg per 100 kcal of energy of the agent of the present invention.
The amount of vitamin C is usually 2 to 10 mg per 100 kcal of energy of the agent of the present invention.
In the present invention, dietary fibers, sweeteners (for example, palatinose, etc.), emulsifiers, and the like can be further blended as components constituting the solid content, if necessary.

  The amount of water is such that the energy per milliliter of the agent of the present invention is preferably 1 to 2 kcal, more preferably 1.2 to 1.9 kcal, particularly preferably 1.4 to 1.8 kcal. It is. If the value is less than 1 kcal, the burden on the kidney is increased for patients with renal insufficiency, etc., whose water intake is limited, which may be undesirable for improving the medical condition. If the value exceeds 2 kcal, the amount of water may be too small for a renal failure patient or the like whose water intake is limited, and it may be difficult to maintain good physical function.

As an example of a preferred embodiment of the present invention, an agent comprising protein, lipid, carbohydrate, mineral and water, the amount of protein is 0.5 to 5 g and the amount of lipid is 1 to 1 per 100 kcal of energy of the agent. 5 g, 10 to 20 g of carbohydrate, 10 to 50 mg of phosphorus, 10 to 100 mg of sodium, 5 to 50 mg of potassium, and 1 to 2 kcal of energy per milliliter Can be mentioned.
In this example, per 100 kcal of energy of the agent, the amount of calcium is 10 to 50 mg, the amount of magnesium is 5 to 30 mg, the amount of iron is 0.2 to 2 mg, the amount of zinc is 0.2 to 2 mg, and vitamin A More preferably, the amount is 10 to 100 μg RE and the amount of vitamin D is 0.1 to 0.5 μg.
According to these preferred embodiments, the effect of reducing protein catabolism or promoting anabolism can be further enhanced.

The volume of one dose of the agent of the present invention (dose for each administration) is preferably 100 to 300 ml, more preferably 100 to 250 ml, further preferably 100 to 200 ml, particularly preferably 100 to 300 ml. 150 milliliters, most preferably 120-130 milliliters. If the value is less than 100 milliliters, the amount of water may be too small for a renal failure patient or the like whose water intake is limited, and it may be difficult to maintain good physical function. When the value exceeds 300 milliliters, the kidney burden increases for patients with renal insufficiency and the like whose water intake is limited, which may be undesirable for improving the medical condition.
The agent of the present invention is preferably used for dialysis patients.

The agent of the present invention is for those whose value obtained by subtracting the value of amino acid concentration in arterial blood in a non-ingested state from the value of amino acid concentration in arterial blood 3 hours after the ingestion of the agent becomes 0 or more It is preferably used as an agent for oral administration.
As a method for determining the necessity of use of the agent of the present invention, from the value of the amino acid concentration in arterial blood after a predetermined time (for example, 1 to 5 hours) after the intake of the agent, The value obtained by subtracting the value of the amino acid concentration is determined. If the value is 0 or more, the agent of the present invention is used. If the value is less than 0 (minus), the agent of the present invention is not used. The method of determining is mentioned.

  The agent of the present invention can be used as an agent for reducing protein catabolism or promoting anabolism. Specifically, it suppresses or prevents muscle loss in a nutritional disorder such as a dialysis patient or a person who has the possibility of it. Can be used as an agent for. The agent of the present invention can also be used as an agent that is not a therapeutic purpose for reducing protein catabolism or promoting anabolism. Specifically, it is a muscle disorder in a person having or possibly having a nutritional disorder such as a dialysis patient. It can also be used as a non-therapeutic agent for the suppression or prevention of the decrease in blood pressure.

  Hereinafter, the present invention will be described by way of examples. However, the present invention is not limited to the following examples, and various embodiments can be adopted as long as they are included in the scope of the claims.

[Intake and blood collection of the agent of the present invention by a subject]
The following experiment was conducted with 10 dialysis patients as subjects.
After the subject ingested breakfast, he visited the hospital and ingested “Meiji Linalen MP” (trade name; manufactured by Meiji Co., Ltd.) corresponding to the agent of the present invention with one bottle, and then received dialysis for 3 hours. When the dialysis for 3 hours was completed, venous blood and arterial blood were collected from the subjects.
In another week, the subject visited the hospital after eating breakfast and received 3 hours of dialysis without taking "Meiji Linalen MP". When the dialysis for 3 hours was completed, venous blood and arterial blood were collected from the subjects.

The capacity, energy, and main components per bottle of “Meiji Linalen MP” are as follows.
(1) Capacity: 125ml (2) Energy: 200kcal
(3) Main components and contents Protein (milk protein): 7.0 g
Lipid (Medium chain fatty acid triglyceride, etc.): 5.6 g
Carbohydrate (dextrin): 29.8g
Sodium: 120mg
Potassium: 60mg
Calcium: 60mg
Magnesium: 30mg
Phosphorus: 70mg
Iron: 1.76 mg
Zinc: 1.50mg
Chlorine: 20mg
Vitamin A: 120 μg RE
Vitamin D: 0.26 μg
Vitamin E: 2.0mg
Vitamin B1: 0.20mg
Vitamin B2: 0.24mg
Vitamin B6: 1.26mg
Vitamin C: 10.0mg
Dietary fiber: 2.0g
Moisture: 94.4g

[Measurement of amino acid concentration in collected blood samples]
The amino acid concentration of the collected blood sample was measured by the following method.
After blood collection, plasma was separated from the blood sample according to a conventional method, and this plasma was placed in a container containing EDTA disodium and stored frozen until measurement. At the time of measurement, the contents in the container were thawed, and after the thawed contents were taken in a volume of 0.5 ml and subjected to protein removal treatment, centrifugation (12,000 rpm, 10 minutes) was repeated twice. The supernatant is collected, and a reaction reagent (trade name: Aminotag Wako for automatic amino acid analysis, manufactured by Wako Pure Chemical Industries, Ltd.) is added to the supernatant, mixed and heated, and the free amino acid as the target component is derived. Turned into. Thereafter, the derivatized free amino acid was analyzed using a high performance liquid chromatography mass spectrometer (trade name: LCMS2020, manufactured by Shimadzu Corporation) to obtain amino acid concentrations (25 types) of the blood sample. At this time, “Inertosyl ODS-3” (trade name; dimensions: φ2.1 × 100 mm, manufactured by GL Sciences Inc.) was used as a column for liquid chromatography.

[Calculation of numerical values a to d]
Based on the amino acid concentration of the collected blood sample, numerical values a to d were obtained from the following equations.
Numerical value a = “concentration of each amino acid in arterial blood when taking the agent of the present invention” − “concentration of each amino acid in arterial blood when not taking the agent of the present invention”
Numerical value b = “concentration of each amino acid in venous blood when the agent of the present invention is ingested” − “concentration of each amino acid in arterial blood when the agent of the present invention is ingested”
Numerical value c = “concentration of each amino acid in venous blood when not taking the agent of the present invention” − “concentration of each amino acid in arterial blood when not taking the agent of the present invention”
Numerical value d = Numerical value b−Numerical value c

The numerical value a indicates the range of increase in the concentration of each amino acid in arterial blood by administration of the agent of the present invention, and is a numerical value that suggests promotion of protein assimilation.
The numerical value b and the numerical value c indicate the degree of protein catabolism when the agent of the present invention is ingested (numerical value b) and when not ingested (numerical value c). A positive value indicates that protein catabolism is promoted, and a negative value indicates that protein assimilation is promoted (in other words, catabolism is reduced). Indicates. That is, taking the numerical value b (when the agent of the present invention is taken) as an example, blood flows from the artery to the vein, so the value obtained by subtracting the amino acid concentration in the arterial blood from the amino acid concentration in the venous blood is The negative value indicates that protein assimilation (synthesis from amino acids) is promoted in peripheral tissues (muscles receiving nutrient supply). Conversely, if the value obtained by subtracting the amino acid concentration in arterial blood from the concentration of amino acid in venous blood is positive, protein catabolism (degradation into amino acids) in peripheral tissues (muscles that receive nutrition) ) Is promoted.
If the numerical value d is negative, it indicates that reduction of protein catabolism (promotion of assimilation) occurs due to the intake of the agent of the present invention.

[Relationship between numerical value d and frequency]
The combination of the number of subjects (10 persons) and amino acid types (25 types) is 250. Each of these 250 combinations is treated as one frequency. Regarding the 244 frequencies excluding the 6 frequencies for which measurement values could not be obtained due to measurement operational problems (below detection sensitivity), (a) when all numerical values a are targeted (the numerical value a is negative) Whether or not; 244 degrees) numerical value d, (b) numerical value d when numerical value a is less than 0 (minus), (c) numerical value d when numerical value a is 0 or more The numerical value d was classified into sections having a width of 10, and the frequencies contained in these sections were examined. The results are shown in Table 1.

In Table 1, when the numerical value a is less than 0 (minus) and the numerical value d is less than 0 (minus), the total number of frequencies included is 32 (part A in Table 1), and the whole (112) The ratio is 28.6%. In addition, when the numerical value a is less than 0, the total number of frequencies included in the category in which the numerical value d is 0 or more is 80 (part B in Table 1), and 71.4% as a ratio in the whole (112) It is.
In the case where the numerical value a is 0 or more and the numerical value d is less than 0 (minus), the total number of frequencies is 61 (part C in Table 1), and 46.2 as a ratio in the whole (132). %. In addition, in the case where the numerical value a is 0 or more, the total number of frequencies included in the category where the numerical value d is 0 or more is 71 (part D in Table 1), and 53.8% as a percentage in the whole (132) It is.

It can be considered as follows that the distribution of the numerical value d is different between the case where the numerical value a is less than 0 (minus) and the case where the numerical value a is 0 or more.
Compared to the case where the agent of the present invention is not taken, the concentration of amino acids in arterial blood is higher when the agent of the present invention is taken (in other words, the numerical value a is positive) or equivalent (in other words, the numerical value a For a subject who has obtained a result of 0), the intake of the agent of the present invention has a frequency (possibility) showing a reduction in protein catabolism (in other words, the numerical value d becomes negative) by 50%. Increase to close (46.2%).

On the other hand, the subject who obtained the result that the concentration of amino acids in arterial blood was lower (in other words, the numerical value a was negative) when the agent of the present invention was ingested than when the agent of the present invention was not ingested. Therefore, even when the agent of the present invention is ingested, the frequency (possibility) showing reduction of protein catabolism (in other words, the numerical value d becomes negative) is as low as 28.6%.
Statistically, there is also a significant relationship between stratification by numerical value a (two-partitioning with 0 as a boundary) and the effect of reducing protein catabolism (whether numerical value d is negative). (Mxn contingency table test: p = 0.0183).

  Therefore, in the agent of the present invention, the value obtained by subtracting the value of the amino acid concentration in arterial blood in a non-ingested state from the value of the amino acid concentration in arterial blood 3 hours after the ingestion of the agent becomes 0 or more. In the case of oral administration to a person, it has been fully confirmed by an actual dialysis patient test that an excellent effect of reducing catabolism or promoting anabolism can be obtained.

  From the above, it was confirmed that the agent of the present invention has an excellent effect of reducing protein catabolism or promoting anabolism. The agent of the present invention is composed of ingredients that have been sufficiently ingested as food, and can be provided not only as a pharmaceutical product but also as a food product. Thereby, the pharmaceutical and foodstuff which have the effect | action which prevents renal diseases, such as a renal failure based on the catabolism reduction | restoration or assimilation promotion effect | action, can also be provided.

Claims (6)

  Protein catabolism reduction or assimilation characterized in that the amount of protein is 0.5 to 5 g, the amount of phosphorus is 10 to 50 mg, the amount of sodium is 10 to 100 mg, and the amount of potassium is 5 to 50 mg per 100 kcal of energy Agent for promotion. An agent for reducing catabolism or promoting anabolism of protein, which can be ingested as a liquid food, including protein, lipid, carbohydrate, mineral and water,
Per 100 kcal of energy, the amount of protein is 0.5-5 g, the amount of lipid is 1-5 g, the amount of carbohydrate is 10-20 g, the amount of phosphorus is 10-50 mg, the amount of sodium is 10-100 mg, the amount of potassium Is 5 to 50 mg,
An agent for reducing protein catabolism or promoting anabolism, wherein the energy per milliliter is 1 to 2 kcal.   Contains vitamins, and per 100 kcal of energy, the amount of calcium is 10-50 mg, the amount of magnesium is 5-30 mg, the amount of iron is 0.2-2 mg, the amount of zinc is 0.2-2 mg, the amount of vitamin A 3 to 100 μg RE, and the amount of vitamin D is 0.05 to 0.5 μg. The agent for reducing catabolism or promoting anabolism according to claim 1 or 2.   The agent for reducing catabolism or promoting anabolism according to any one of claims 1 to 3, wherein the volume of a single dose is 100 to 300 ml.   The agent for reducing protein catabolism or promoting anabolism according to any one of claims 1 to 4, for use in a dialysis patient.   The above-mentioned agent for reducing catabolism or promoting anabolism is a value obtained by subtracting the value of amino acid concentration in arterial blood in a non-intake state from the value of amino acid concentration in arterial blood 3 hours after the intake of the agent The agent for reducing catabolism or promoting anabolism according to any one of claims 1 to 5, which is for oral administration to those who become 0 or more.